share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  08/09 16:36

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company has not generated any revenue to date and continues to incur significant operating losses. The net loss for the quarter was approximately $2.8 million, a significant improvement from the net loss of $78.5 million for the same period in the previous year. This reduction in net loss was primarily due to the absence of impairment charges that were recorded in the prior year. Research and development expenses decreased by 41.9% to $709,049, while general and administrative expenses also saw a reduction of 48% to $2,044,929. The company's cash position as of June 30, 2024, was $119,486, a decrease from $3,137,674 at the end of 2023. ZyVersa is focused on the development of drugs for patients with chronic renal or inflammatory diseases and has not yet achieved profitability. The company's future plans include progressing the development of its lead product candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations and potential commercialization.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company has not generated any revenue to date and continues to incur significant operating losses. The net loss for the quarter was approximately $2.8 million, a significant improvement from the net loss of $78.5 million for the same period in the previous year. This reduction in net loss was primarily due to the absence of impairment charges that were recorded in the prior year. Research and development expenses decreased by 41.9% to $709,049, while general and administrative expenses also saw a reduction of 48% to $2,044,929. The company's cash position as of June 30, 2024, was $119,486, a decrease from $3,137,674 at the end of 2023. ZyVersa is focused on the development of drugs for patients with chronic renal or inflammatory diseases and has not yet achieved profitability. The company's future plans include progressing the development of its lead product candidates, VAR 200 and IC 100, and seeking additional funding to support ongoing operations and potential commercialization.
丝维萨治疗公司是一家处于临床阶段的生物制药公司，公布了截至2024年6月30日的财务报告。该公司迄今为止尚未实现任何营业收入并继续产生巨大的营运亏损。本季度净亏损约为280万美元，相较于去年同期的净亏损7,850万美元，取得了显著改善。净亏损的降低主要是由于前一年记录的减值费用不再存在。研发费用减少了41.9％至709,049美元，而总务及行政费用也减少了48％至2,044,929美元。截至2024年6月30日，该公司的现金储备为119,486美元，较2023年底的3,137,674美元有所减少。丝维萨致力于为患有慢性肾脏或炎症性疾病的患者开发药物，目前尚未实现盈利。该公司未来的计划包括推进其主导产品VAR 200和IC 100的开发，并寻求额外的资金支持持续营运和潜在的商业化。
丝维萨治疗公司是一家处于临床阶段的生物制药公司，公布了截至2024年6月30日的财务报告。该公司迄今为止尚未实现任何营业收入并继续产生巨大的营运亏损。本季度净亏损约为280万美元，相较于去年同期的净亏损7,850万美元，取得了显著改善。净亏损的降低主要是由于前一年记录的减值费用不再存在。研发费用减少了41.9％至709,049美元，而总务及行政费用也减少了48％至2,044,929美元。截至2024年6月30日，该公司的现金储备为119,486美元，较2023年底的3,137,674美元有所减少。丝维萨致力于为患有慢性肾脏或炎症性疾病的患者开发药物，目前尚未实现盈利。该公司未来的计划包括推进其主导产品VAR 200和IC 100的开发，并寻求额外的资金支持持续营运和潜在的商业化。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间